Explore

Evidence-backed clinical questions

1. Does dapagliflozin vs placebo affect OUT:cv-death-or-worsening-hf in Heart Failure with Reduced Ejection Fraction? — 1 studies (4,744 patients, 1 RCTs) provide moderate-certainty evidence for benefit of dapagliflozin for Composite of worsening HF or cardiovascular death in Heart Failure with Reduced Ejection Fraction.
2. Does dabigatran vs warfarin improve outcomes in HEART-VALVE, MECHANICAL? — 25 studies (732,515 patients) provide low-certainty evidence for benefit of dabigatran for Ventricular Arrhythmia in HEART-VALVE, MECHANICAL.
3. Does immune checkpoint inhibitors vs placebo improve outcomes in cancer therapy-related cardiovascular toxicity? — 25 studies (460,637 patients) provide low-certainty evidence for benefit of immune checkpoint inhibitors for Cardiac Index in cancer therapy-related cardiovascular toxicity.
4. Does rivaroxaban vs apixaban improve outcomes in Venous Thromboembolism? — 5 studies (48,024 patients) provide low-certainty evidence for benefit of rivaroxaban for Cardiac Output in Venous Thromboembolism.
5. Does ticagrelor vs clopidogrel improve Myocardial Infarction Hospitalization in Acute Coronary Syndrome? — 3 studies (41,464 patients) provide low-certainty evidence for benefit of ticagrelor for Myocardial Infarction Hospitalization in Acute Coronary Syndrome.
6. Does inspiratory muscle training (imt) vs placebo improve Peak Oxygen Consumption in Heart Failure, Diastolic? — 2 studies (1,483 patients) provide low-certainty evidence for benefit of inspiratory muscle training (imt) for Peak Oxygen Consumption in Heart Failure, Diastolic.
7. Does ezetimibe vs statin improve outcomes in Acute Coronary Syndrome? — 2 studies (82 patients) provide low-certainty evidence for benefit of ezetimibe for Cardiac Output in Acute Coronary Syndrome.
8. — 10 studies (49,075 patients) provide low-certainty evidence against benefit of amiodarone for Myocardial Infarction Hospitalization in Atrial Fibrillation.